NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 124 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,416 | -61.2% | 12,538 | -6.0% | 0.00% | – |
Q2 2023 | $34,538 | -76.1% | 13,335 | -62.3% | 0.00% | – |
Q1 2023 | $144,461 | -46.1% | 35,407 | -33.7% | 0.00% | -100.0% |
Q4 2022 | $268,204 | -75.8% | 53,427 | -37.1% | 0.00% | -50.0% |
Q3 2022 | $1,110,000 | +38.1% | 84,886 | +35.4% | 0.00% | 0.0% |
Q2 2022 | $804,000 | +81.1% | 62,687 | +115.5% | 0.00% | +100.0% |
Q1 2022 | $444,000 | +98.2% | 29,091 | +107.0% | 0.00% | 0.0% |
Q3 2020 | $224,000 | -30.2% | 14,057 | -13.5% | 0.00% | 0.0% |
Q2 2020 | $321,000 | – | 16,254 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |